The most significant long-term health risk of this transition – what changes, why it matters, and the complete evidence-based approach to protection

The Health Risk That Eclipses All Others

Women in perimenopause and menopause worry about hot flushes, weight gain, and bone density. They are less likely to worry about heart disease – even though cardiovascular disease is, by a very large margin, the leading cause of death in women and the health risk most dramatically altered by the menopausal transition.

The risk of cardiovascular disease notably increases in the fifth decade of a woman’s life, coinciding with the onset of menopause and occurring approximately 10 years later than the similar age-related increase in men. Epidemiological investigation has shown that the incidence of cardiovascular disease in premenopausal women is lower than in men, and the incidence in postmenopausal women is significantly higher than in men of the same age.

This sex-specific transition – from cardiovascular protection to cardiovascular vulnerability – is not simply a consequence of ageing. It is mechanistically linked to the hormonal change of the menopausal transition, driven by the loss of estrogen’s comprehensive cardiovascular protective effects. And it is not simply a story about old age: the groundwork for these risks is laid during perimenopause itself, beginning years before the final menstrual period.

This article explains the complete picture: the mechanisms through which estrogen protects the heart, the changes that perimenopause and menopause impose on the cardiovascular system, the evidence on hormone therapy and the timing hypothesis, and the full evidence-based lifestyle and medical prevention strategy.

Part 1: Estrogen as Cardiovascular Protector

The Broad Architecture of Estrogen’s Cardiovascular Effects

Estrogen’s protective role in cardiovascular health is one of the most extensively documented facts in cardiology. Its mechanisms are multiple, simultaneous, and operate at every level of the cardiovascular system:

Endothelial function and vasodilation. The endothelium – the single-cell layer lining every blood vessel – is the primary site of estrogen’s cardiovascular action. Estrogen stimulates the production of nitric oxide (NO) by endothelial cells through direct activation of endothelial nitric oxide synthase (eNOS). Nitric oxide is the most potent endogenous vasodilator: it relaxes vascular smooth muscle, reduces blood pressure, inhibits platelet aggregation, and prevents the adhesion of inflammatory cells to the vessel wall. Perimenopause is a pivotal phase in determining long-term health for cardiovascular disease, with women already showing early indicators of endothelial dysfunction during this period.

Lipid profile maintenance. Estrogen actively manages the lipid profile in a cardioprotective direction: it raises HDL (high-density lipoprotein – the “good” cholesterol), lowers LDL (low-density lipoprotein), reduces lipoprotein(a) – an independent and potent cardiovascular risk factor – and reduces triglycerides. When estrogen falls, this favorable profile reverses: total cholesterol rises, LDL increases, HDL falls, and triglycerides increase, sometimes dramatically.

Anti-inflammatory effects. Estrogen directly suppresses the production of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and reduces C-reactive protein – the most widely used clinical marker of systemic inflammation and cardiovascular risk. When estrogen withdraws, low-grade systemic inflammation rises, creating the atherosclerosis-promoting environment characteristic of postmenopause.

Arterial stiffness and blood pressure. Estrogen maintains the elasticity of the arterial wall – its capacity to expand and recoil with each heartbeat. When estrogen falls, arterial stiffness increases, pulse wave velocity rises (a measure of arterial age), and systolic blood pressure climbs. Blood pressure rises markedly in the perimenopausal years – not because of ageing per se, but because of the loss of estrogen’s vasodilatory and anti-inflammatory arterial effects.

Cardiac structure. Estrogen receptors are present in cardiomyocytes (heart muscle cells) and modulate cardiac hypertrophy, oxidative stress in cardiac tissue, and myocardial function directly. Estrogen deficiency is associated with increased paracardial fat deposition – fat deposits around the heart muscle that are particularly harmful given their direct proximity to the myocardium and their role in secreting inflammatory cytokines.

What Changes During Perimenopause – Before Menopause

One of the most important insights from recent cardiovascular research concerns the timing of when risk begins to accumulate. Perimenopause itself – the years of hormonal fluctuation before the final menstrual period – is when the earliest cardiovascular changes occur:

The decline in estrogen during the menopause transition induces adverse metabolic changes that increase the risk of dyslipidemia, obesity, insulin resistance, atherogenesis, and poor downstream outcomes such as diabetes, hypertension, stroke, and other adverse changes. Research suggests that women in perimenopause already have early indicators of hypertension, oxidative stress, and endothelial dysfunction, making them more vulnerable to cardiovascular disease in the long run.

The trajectory of risk is continuous – it does not begin at menopause. It begins during perimenopause, and in some cases during early perimenopause when estrogen is still measurable, but its fluctuation is already sufficient to disrupt endothelial function and lipid metabolism. The groundwork for these risks is laid much earlier, making it essential to understand these phases as part of a continuous process rather than isolated events.

The Lipid Transition: A Concrete Illustration

The lipid changes of perimenopause provide a clear illustration of how rapidly the cardiovascular risk profile shifts:

In the reproductive years, women typically have higher HDL and lower LDL than age-matched men – a profile that translates directly to lower atherosclerotic risk. As estrogen falls, LDL rises by an average of 10–15%, HDL falls by 5–10%, and triglycerides increase by 15–20% in the first 3–5 years after menopause. These are not minor changes – they represent a shift in the atherogenic profile comparable to several decades of male cardiovascular risk accumulation, compressed into a few years.

Hot Flushes as a Cardiovascular Signal

One of the most important recent findings in cardiovascular medicine concerns the relationship between vasomotor symptoms (hot flushes and night sweats) and cardiovascular risk. This is not simply a temporal association – it is mechanistically coherent.

Frequent, severe hot flushes are associated with adverse changes in cardiovascular biomarkers, including measures of subclinical atherosclerosis (carotid intima-media thickness, coronary artery calcification), inflammatory markers, and endothelial function. This finding has been replicated across multiple cohort studies and suggests that vasomotor symptoms are a marker of underlying vascular vulnerability – the same estrogen-deficient arterial environment that produces flushing also produces accelerated atherogenesis.

A 2025 analysis published in JAMA Internal Medicine – examining menopausal hormone therapy and cardiovascular disease in women with vasomotor symptoms specifically – confirmed that MHT is neutral for heart risk in symptomatic younger women, reaffirming that treating vasomotor symptoms appropriately does not worsen cardiovascular outcomes.

Part 2: The WHI, the Timing Hypothesis, and What the Evidence Now Shows

The Women’s Health Initiative – What It Actually Said and What It Did Not

No discussion of cardiovascular health during menopause can begin without addressing the Women’s Health Initiative (WHI) trial – the study that fundamentally disrupted hormone therapy prescribing for two decades and whose misinterpretation continues to harm women today.

The WHI enrolled postmenopausal women averaging 63 years of age – more than a decade beyond menopause – many of whom had pre-existing cardiovascular disease or risk factors. The combined estrogen-plus-progestin arm (using oral conjugated equine estrogens and synthetic medroxyprogesterone acetate) was halted in 2002 when early data suggested excess risk of breast cancer and cardiovascular events. The media and clinical response was an almost complete abandonment of hormone therapy prescribing – including in perimenopausal and recently menopausal women for whom the WHI results were never applicable.

Hormone replacement therapy faced significant scrutiny following the Women’s Health Initiative trial. Contemporary evidence demonstrates that cardiovascular outcomes vary considerably based on formulation, route of administration, timing of initiation, and patient-specific factors. Modern strategies emphasize individualized patient selection, lower-dose regimens, and transdermal delivery methods. The “timing hypothesis” proposes that HRT initiated within 10 years of menopause onset or before age 60 may confer cardiovascular benefit, whereas later initiation may increase cardiovascular risk.

The Timing Hypothesis – The Central Clinical Framework

The resolution of the apparent contradiction between the WHI findings (harm) and the extensive pre-WHI observational and biological evidence (benefit) is the timing hypothesis. Age-stratified analyses of WHI data with median follow-up of 13 years showed that absolute risks of adverse events after hormone therapy initiation were much lower in women aged 50–59 than in those who were older, and also lower in those who started within 10 years of menopause onset.

The ELITE trial (Early versus Late Intervention Trial with Estradiol) – the most rigorous randomized controlled trial of the timing hypothesis – provided definitive evidence: women who started transdermal estradiol within 6 years of menopause showed significantly less progression of carotid intima-media thickness (a measure of atherosclerosis) compared to women who started 10 or more years after menopause, where no benefit was seen.

The clinical interpretation is clear and now forms the basis of guidance from the American Heart Association, The Menopause Society, and the British Menopause Society: when started early – before age 60, or within 10 years of the final menstrual period – modern MHT does not increase cardiovascular risk for most healthy women and may reduce it. When started late (more than 10 years post-menopause, or in women with established cardiovascular disease), the benefit-risk profile changes unfavorably.

Modern research confirms that MHT does not increase heart disease risk for most healthy women under 60 or within 10 years of menopause. When started early, MHT can reduce cardiovascular risk by 30–50% by supporting blood vessel flexibility, reducing inflammation, and lowering lipoprotein(a) levels.

The Formulation and Route Difference – Why Transdermal Is Preferred

Not all hormone therapy is equal from a cardiovascular standpoint, and the formulation distinction is clinically critical:

Oral estrogen undergoes first-pass hepatic metabolism, stimulating the production of clotting factors II, VII, and X in the liver – increasing thrombotic risk – and raising inflammatory markers including C-reactive protein. The ESTHER study demonstrated that oral estrogen users faced a 4-fold higher risk of blood clots compared to non-users, while transdermal estradiol users had no increased risk.

Transdermal estradiol (gel, patch, or spray) bypasses first-pass metabolism entirely. It delivers stable, physiological estradiol levels without hepatic stimulation of clotting factors, without raising C-reactive protein, and – according to a 2025 meta-analysis of 23 studies – reduces systolic blood pressure by an average of 3.2 mmHg in postmenopausal women, while oral estrogens showed no consistent effect.

The progestogen component also matters. Medroxyprogesterone acetate (MPA – the synthetic progestin used in the WHI trial) has androgenic and glucocorticoid properties that partially offset the beneficial cardiovascular effects of estrogen and are associated with worsened lipid profiles and inflammatory markers. Oral micronized progesterone (OMP) – the bioidentical, natural progesterone – does not share these properties and appears to be cardiovascular-neutral or modestly beneficial.

The current evidence-based recommendation is clear: for women with cardiovascular risk considerations, transdermal estradiol plus oral micronized progesterone represents the safest and most beneficial hormone therapy formulation from a cardiovascular perspective.

Part 3: Cardiovascular Risk Factors During This Transition – The Full Picture

Hypertension: The Silent Rising Risk

Blood pressure rises significantly during and after the menopausal transition. The mechanism is multifactorial: loss of estrogen’s vasodilatory effect through reduced nitric oxide production; increased arterial stiffness; altered renin-angiotensin-aldosterone system activity; increased sympathetic nervous system reactivity; and weight gain with its associated sodium retention. Hypertension is both the most common cardiovascular risk factor in postmenopausal women and the most modifiable.

Target for midlife women: systolic blood pressure below 130 mmHg (the American Heart Association 2025 guidance). Blood pressure measurement should be performed at home (averaging two readings, morning and evening) in addition to clinic measurements, which frequently overestimate blood pressure due to white coat hypertension.

Dyslipidemia: The Shifting Lipid Profile

As described above, the lipid profile shifts unfavorably at menopause. The specific changes most important for cardiovascular risk assessment in perimenopausal women:

Lipoprotein(a) – an independent cardiovascular risk factor that rises significantly at menopause, particularly in genetically susceptible women. It is not included in standard lipid panels – it must be specifically requested. Elevated lipoprotein(a) above 50 mg/dL substantially increases atherosclerotic risk and is partially modifiable with transdermal estrogen (which reduces it) and, where indicated, specific pharmacological options (PCSK9 inhibitors, emerging RNA interference therapies targeting LPA).

Triglycerides – the lipid parameter most responsive to dietary carbohydrate intake and insulin resistance. Elevated triglycerides (above 2.3 mmol/L or 200 mg/dL) in the context of low HDL and high waist circumference defines the atherogenic lipid triad that characterizes menopausal metabolic syndrome.

Small dense LDL – standard LDL measurement does not capture LDL particle size, and it is the small, dense LDL particles (rather than LDL mass) that most reliably predict atherosclerosis risk. These are best assessed through advanced lipid panels (apolipoprotein B, LDL-P, or NMR-based testing), which are increasingly available.

Subclinical Atherosclerosis: The Hidden Process

Atherosclerosis – the progressive narrowing and stiffening of arteries through plaque formation – begins in the perimenopausal years for many women, typically 10–15 years before it produces symptoms or clinical events. It can be directly visualized through:

Carotid intima-media thickness (cIMT) – ultrasound measurement of the carotid artery wall thickness, used in research and increasingly in clinical practice as a marker of subclinical cardiovascular disease.

Coronary artery calcium (CAC) scoring – CT-based measurement of calcium deposits in the coronary arteries, providing a direct assessment of atheromatous plaque burden. A CAC score of 0 in a symptomatic perimenopausal woman provides strong reassurance; progressive scores guide the intensity of preventive intervention.

The Unique Cardiovascular Risk Factors of the Reproductive History

Certain pregnancy- and reproductive-history-based risk factors are now incorporated into cardiovascular risk assessment for women:

History of pre-eclampsia – associated with a 2-fold increase in subsequent cardiovascular disease risk; reflects underlying endothelial and renal vulnerability that pregnancy unmasks.

History of gestational diabetes – associated with a 7-fold increased risk of subsequent type 2 diabetes and substantially elevated cardiovascular risk.

Premature menopause (before 45) – associated with higher long-term cardiovascular risk, independent of age, with a clear indication for early hormone therapy unless contraindicated.

PCOS (polycystic ovary syndrome) – associated with metabolic syndrome, insulin resistance, and elevated cardiovascular risk that persists into and beyond the menopausal transition.

Part 4: The Evidence-Based Prevention Strategy

1. Lifestyle: The Foundation That No Medication Substitutes

Physical activity – the single most evidence-supported cardiovascular intervention:

Regular aerobic exercise reduces cardiovascular mortality by 35%, reduces blood pressure, improves HDL, reduces inflammation, improves endothelial function, and reduces body weight. For postmenopausal women specifically, exercise produces measurable improvements in arterial stiffness and endothelial function that partially compensate for estrogen’s loss at the vascular level.

The evidence-based prescription: at least 150 minutes of moderate-intensity aerobic activity weekly (brisk walking, cycling, swimming) or 75 minutes of vigorous activity. Resistance training two to three times weekly improves insulin sensitivity, reduces metabolic syndrome components, and supports healthy body composition. Muscle strength – measured by grip strength and lower limb power – is an independent predictor of cardiovascular mortality in midlife women.

Dietary pattern:

The Mediterranean diet is the most extensively evidence-supported dietary intervention for cardiovascular disease prevention. Its components – abundant vegetables, legumes, whole grains, olive oil, oily fish, nuts, and moderate red wine in some versions – produce consistent reductions in LDL, inflammation, blood pressure, and atherosclerotic progression across multiple large randomized trials and meta-analyses.

The PREDIMED trial – one of the largest dietary intervention trials for cardiovascular disease prevention – demonstrated a 30% reduction in major cardiovascular events in high-risk individuals randomized to a Mediterranean diet supplemented with olive oil or nuts versus a low-fat control diet.

Smoking cessation:

Smoking is the most powerful reversible cardiovascular risk factor at any age. In perimenopausal women, it accelerates atherosclerosis, raises cardiovascular risk to levels approaching that of diabetic women, and – by competing with estrogen for receptor binding – accelerates the onset of menopause by an average of 2 years. Cessation at any age produces cardiovascular benefit; the benefit is greatest when cessation occurs before the age of 50.

Weight management:

Even modest weight loss (5–10%) produces disproportionately large improvements in blood pressure, HDL, triglycerides, insulin sensitivity, and inflammatory markers – all of which are worsening during the menopausal transition. The Mediterranean dietary pattern plus progressive resistance training plus post-meal walking provides the most evidence-supported combination for menopausal weight management.

Alcohol:

Moderate alcohol consumption in women – particularly in the context of hormonal changes and elevated cardiovascular risk – carries risks (including breast cancer risk and blood pressure elevation) that exceed the modest cardiovascular benefits historically attributed to it. Current guidance from major cardiovascular societies is to limit alcohol to no more than one standard drink per day, with more conservative guidance from public health bodies (UK MHRA 2023) suggesting no “safe” level.

2. Targeted Supplementation: What the Evidence Supports

Omega-3 fatty acids (EPA and DHA) – at doses of 2–4g daily, reduce triglycerides by 20–30% (the strongest evidence-based effect of any supplement on cardiovascular risk), reduce cardiovascular inflammation, and modestly reduce blood pressure. The REDUCE-IT trial demonstrated a 25% reduction in major cardiovascular events with high-dose icosapentaenoic acid (EPA) in statin-treated patients with elevated triglycerides – the most impactful supplement trial in cardiovascular medicine.

Magnesium – deficiency (prevalent in 40–60% of postmenopausal women) is independently associated with hypertension, arrhythmia, and elevated cardiovascular risk. Magnesium glycinate (300–400 mg daily) improves endothelial function, reduces blood pressure modestly, and supports the cardiac electrophysiology affected by menopausal hormonal change.

Coenzyme Q10 – a mitochondrial energy co-factor present in cardiac muscle; supplementation (200–400 mg daily) is associated with modest blood pressure reduction and improved cardiac function in women with elevated cardiovascular risk.

Vitamin D – deficiency is associated with hypertension, endothelial dysfunction, and increased cardiovascular mortality. Correcting to above 50 nmol/L with supplementation is evidence-supported as a component of cardiovascular risk reduction in postmenopausal women.

Berberine – emerging evidence for lipid-lowering effects (reducing LDL and triglycerides) and insulin-sensitizing properties that collectively address several cardiovascular risk factors simultaneously; 500 mg twice daily.

3. Blood Pressure Management

Blood pressure control is the most impactful single modifiable cardiovascular risk factor in postmenopausal women. The lifestyle interventions above (exercise, Mediterranean diet, weight management, reduced sodium, reduced alcohol) should be tried first and are effective for stage 1 hypertension (130–139/80–89 mmHg) with sustained effort.

For women with stage 2 hypertension (≥140/90 mmHg) or stage 1 with other cardiovascular risk factors, pharmacological treatment is indicated alongside lifestyle modification. ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, and low-dose thiazide diuretics are all appropriate first-line options in postmenopausal women without specific contraindications. The choice should be guided by comorbidities – calcium channel blockers are preferred for women with isolated systolic hypertension; ACE inhibitors or ARBs for women with diabetes or proteinuria.

4. Lipid Management

Statins are the most evidence-supported pharmacological intervention for cardiovascular prevention, reducing major cardiovascular events by 25–35% per mmol/L reduction in LDL. For women with moderate to high cardiovascular risk (10-year risk above 7.5% on QRISK3 or PCE calculators), statin therapy is clinically indicated and should not be withheld based on concerns about muscle side effects that are less common at current lower-dose regimens.

A clinical caveat: statins can worsen insulin sensitivity and slightly increase diabetes risk – a consideration in the context of perimenopausal insulin resistance. This risk is dose-dependent, is outweighed by cardiovascular benefit in most moderate-to-high-risk women, and should be factored into the individual risk-benefit discussion.

PCSK9 inhibitors (evolocumab, alirocumab) – monoclonal antibodies that dramatically reduce LDL (by 50–60% additional reduction from statins) and are the only available pharmacological intervention that consistently reduces lipoprotein(a). Indicated for women with very high cardiovascular risk or familial hypercholesterolaemia.

5. Aspirin – No Longer Routinely Recommended

Previous guidance recommended low-dose aspirin (75–100 mg daily) for primary prevention of cardiovascular disease in women over 50. Current evidence – including the USPSTF 2022 update – does not support aspirin for primary prevention in women without established cardiovascular disease, due to gastrointestinal bleeding risk that outweighs cardiovascular benefit in most women without prior events. Aspirin remains recommended for secondary prevention (after a cardiovascular event).

6. Hormone Therapy: Within the Window of Opportunity

The cardiovascular evidence on MHT is now clear enough to be incorporated into prevention discussions. For women who are appropriate candidates – below 60, within 10 years of menopause, without established cardiovascular disease or significant risk factors for thrombosis – transdermal estradiol with oral micronized progesterone does not increase cardiovascular risk and is associated with:

• Improved endothelial function and reduced arterial stiffness
• Favorable lipid profile effects (raised HDL, reduced LDL, reduced lipoprotein(a) and triglycerides)
• Reduced blood pressure with transdermal delivery
• Reduced visceral fat accumulation (up to 60% reduction)
• Improved insulin sensitivity
• Reduction in vasomotor symptoms, which are themselves a cardiovascular risk marker

MHT is not approved specifically for cardiovascular disease prevention and should not be initiated solely for this purpose. But for women with menopausal symptoms who are within the therapeutic window, the cardiovascular considerations are part of the benefit picture – not a source of concern for appropriately selected candidates.

Part 5: The Cardiovascular Assessment – Your Personal Risk Picture

Every perimenopausal and recently postmenopausal woman should have access to a comprehensive cardiovascular risk assessment. The following represents the evidence-based minimum:

Annual measurements:

• Blood pressure (home monitoring, average of 2 readings morning and evening over 7 days)
• Waist circumference (target below 80 cm)
• BMI and weight trend

At least every 5 years (or more frequently if abnormal):

• Full fasting lipid panel including triglycerides and HDL
• Fasting glucose and HbA1c
• Lipoprotein(a) – once, as it is largely genetically determined and does not change significantly with treatment

Consider requesting:

• 10-year cardiovascular risk calculation (QRISK3 in the UK; Pooled Cohort Equations in the US)
• Coronary artery calcium scoring – for women with borderline or intermediate 10-year risk where the result would change clinical management
• Advanced lipid panel (apolipoprotein B) – provides the most accurate LDL particle risk assessment
• High-sensitivity C-reactive protein (hsCRP) – a cardiovascular inflammation marker that is often elevated in perimenopausal women

The Conclusion

Cardiovascular disease is the most common cause of death in women – and the menopausal transition is when the risk trajectory pivots. The loss of estrogen’s vasodilatory, lipid-modifying, anti-inflammatory, and endothelium-protective effects does not simply accelerate a background ageing process. It produces a rapid, measurable deterioration in multiple cardiovascular risk parameters simultaneously, beginning in perimenopause and accelerating through the postmenopausal decade.

The evidence-based response to this is comprehensive, evidence-graded, and now well-established:

Lifestyle first – exercise, Mediterranean diet, smoking cessation, weight management – the interventions that no medication substitutes. Risk assessment with appropriate biomarkers, including lipid panel, blood pressure, glucose, and where indicated, lipoprotein(a) and CAC scoring. Targeted pharmacological management of elevated blood pressure and dyslipidemia. And for appropriate candidates – below 60 and within the therapeutic window – transdermal estradiol with oral micronized progesterone, which does not harm the heart in this population and may meaningfully protect it.

The most harmful legacy of the WHI misinterpretation is not the cancellation of hormone therapy trials. It is the two decades during which women who were within the window of greatest cardiovascular benefit were denied treatment – and the cardiovascular events that resulted. Modern medicine has corrected this narrative. Women and their clinicians should know it.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Sources

1. Uddenberg ER et al. Menopause transition and cardiovascular disease risk. Maturitas. 2024;185:107974. PMC. doi:10.1016/j.maturitas.2024.107974
2. PMC12352403. Cardiovascular Health During Menopause Transition: The Role of Traditional and Nontraditional Risk Factors. Methodist DeBakey Cardiovascular Journal. 2025. doi:10.14797/mdcvj.1619
3. MDPI Journal of Clinical Medicine. Cardiovascular Disease Risk in Women with Menopause.2025;14(11):3663. doi:10.3390/jcm14113663
4. Santoro N et al. Menopause and Cardiovascular Disease, Health Risks. The Cardiology Advisor / ENDO 2025 plenary coverage. thecardiologyadvisor.com. November 2025.
5. PMC8260319. Protective Effects of Estrogen on Cardiovascular Disease Mediated by Oxidative Stress.Oxidative Medicine and Cellular Longevity. 2021. doi:10.1155/2021/5523516
6. Manson JE et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506–e532. doi:10.1161/CIR.0000000000000912
7. PMC12872825. The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review. 2025.
8. Formblends. HRT and Heart Health: Cardiovascular Benefits and Risks in 2026. formblends.com. April 2026. (Citing: ESTHER study; 2025 meta-analysis 23 studies transdermal BP)
9. MyAlloy / Alloy Women’s Health. Is HRT Safe for the Heart? 2026 Safety & Risks Guide. myalloy.com. January 2026. (Citing: ELITE Trial; KEEPS Trial; TMS 2022 position statement)
10. Patient Care Online / Boivin J MD. Hormone Replacement Therapy After the WHI: Clinician’s Evidence Timeline (2002–2025). patientcareonline.com. 2025.
11. Cleveland Clinic / Boushra M MD. Menopausal Hormone Therapy and Heart Risk: Updated Guidance Is at Hand. consultqd.clevelandclinic.org. March 2026. (Citing: WHI 13-year age-stratified follow-up; JAMA Internal Medicine 2025)
12. Manson JE, Crandall CJ, Rossouw JE et al. The Women’s Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748–1760. doi:10.1001/jama.2024.6542
13. Minneapolis Heart Institute Foundation / MHIF Panel 2025. How does menopausal hormone therapy affect heart health? mplsheart.org. September 2025.
14. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi:10.3109/13697137.2015.1129166
15. Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
16. Bhatt DL et al. Cardiovascular Risk Reduction with Icosapentaenoic Acid for Hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine. 2019;380(1):11–22. doi:10.1056/NEJMoa1812792
17. Estruch R et al. Primary prevention of cardiovascular disease with a Mediterranean Diet (PREDIMED). New England Journal of Medicine. 2013;368(14):1279–1290. doi:10.1056/NEJMoa1200303 (Updated analysis 2018)
18. Harman SM et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (ELITE Study). Annals of Internal Medicine. 2014;161(4):249–260. doi:10.7326/M14-0353
19. British Menopause Society. BMS consensus statement: HRT and cardiovascular disease. thebms.org.uk. Updated 2024.
20. USPSTF. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons. JAMA. 2022;328(17):1740–1746. doi:10.1001/jama.2022.18583